Singapore, Singapore

Elvin Koh

This inventor holds 2 USPTO granted patents. Top assignees: Nanyang Technological University, National University of Singapore. Active years: 2017-2026.


% Patents Active = 50.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2017-2026

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Elvin Koh: Innovator in Pathogen Detection and Control

Introduction

Elvin Koh is a notable inventor based in Singapore, recognized for his contributions to the field of biotechnology. His innovative work focuses on the detection and control of pathogenic microorganisms, which is crucial for public health and safety.

Latest Patents

Elvin Koh holds a patent for an isolated nucleotide molecule and a method of sensing and killing pathogenic microorganisms. This invention involves an isolated nucleic acid molecule that encodes a protein capable of detecting pathogenic microorganisms by forming a complex with a quorum sensing molecule produced by these microorganisms. The patent also describes a recombinant microorganism that utilizes this isolated nucleic acid molecule, providing a method for effectively sensing and eliminating harmful pathogens.

Career Highlights

Elvin Koh is affiliated with Nanyang Technological University, where he contributes to research and development in biotechnology. His work has significant implications for improving health outcomes through innovative detection methods.

Collaborations

Elvin has collaborated with notable colleagues, including Matthew Wook Chang and In Young Hwang, enhancing the impact of his research through teamwork and shared expertise.

Conclusion

Elvin Koh's innovative contributions to pathogen detection and control exemplify the importance of biotechnology in addressing health challenges. His work continues to pave the way for advancements in microbial management and public health safety.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…